FKBP9 enhances IGF2BP1-mediated m6A recognition to promote hepatocellular carcinoma progression

This study highlights the critical role of FKBP9 in hepatocellular carcinoma progression by regulating IGF2BP1-mediated m6A RNA recognition, thereby enhancing the stability of key oncogenic transcripts such as <i>MYC</i> and <i>PDGFB</i>. These findings provide new insights into the molecular mechanisms driving hepatocellular carcinoma and identify potential therapeutic opportunities for patients with poor prognosis linked to high FKBP9 expression. The FKBP9-IGF2BP1 axis may serve as both a biomarker and a therapeutic target to guide the development of new treatment strategies. Further studies are warranted to validate these results in larger patient cohorts and to assess the clinical feasibility of targeting this pathway.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2025-09-23
DOI
https://doi.org/10.1016/j.jhepr.2025.101584
Primary Topic
RNA modifications and cancer
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FKBP9 enhances IGF2BP1-mediated m6A recognition to promote hepatocellular carcinoma progression

Yanuo Chen, Zhengqing Lei, Fangliang Xie, Anfeng Si et al.
JHEP Reports
RNA modifications and cancer
article

FKBP9 enhances IGF2BP1-mediated m6A recognition to promote hepatocellular carcinoma progression

Yanuo Chen, Zhengqing Lei, Fangliang Xie, Anfeng Si, Xuewu Tang, Tongfeng Liu, Yongbo Pan, Weihu Ma, Zhangjun Cheng, Jiang Zhu, Shan Gao, Facai Yang, Yigang He, Yinmin Gu, Cheng Chi, Hongping Xia, Qiushi Yu
article en

Abstract

This study highlights the critical role of FKBP9 in hepatocellular carcinoma progression by regulating IGF2BP1-mediated m6A RNA recognition, thereby enhancing the stability of key oncogenic transcripts such as <i>MYC</i> and <i>PDGFB</i>. These findings provide new insights into the molecular mechanisms driving hepatocellular carcinoma and identify potential therapeutic opportunities for patients with poor prognosis linked to high FKBP9 expression. The FKBP9-IGF2BP1 axis may serve as both a biomarker and a therapeutic target to guide the development of new treatment strategies. Further studies are warranted to validate these results in larger patient cohorts and to assess the clinical feasibility of targeting this pathway.

JHEP ReportsVol. 7(12)
Guiyang Medical University (CN), Xuzhou Medical College (CN), Guizhou University (CN), Nanjing General Hospital of Nanjing Military Command (CN), Zhongda Hospital Southeast University (CN), The First People’s Hospital of Lianyungang (CN), Southeast University (CN), Nanjing University (CN)
Jiangsu Commission of Health, National Natural Science Foundation of China, Government of Jiangsu Province, Southeast University, National Science and Technology Major Project
Openalex Percentile: Top 77%
RNA modifications and cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.